journal
MENU ▼
Read by QxMD icon Read
search

Cancer Treatment Reports

journal
https://www.readbyqxmd.com/read/2891441/phase-i-trial-of-taxol-in-patients-with-advanced-cancer
#1
R C Donehower, E K Rowinsky, L B Grochow, S M Longnecker, D S Ettinger
Taxol is a unique plant-derived antineoplastic agent that appears to exert its cytotoxic effect by interfering with microtubule structure and function. In this phase I trial, in which the drug was given as a brief iv infusion every 3 weeks, the dose-limiting toxicity was leukopenia, with thrombocytopenia being seen much less frequently. Sensory neuropathy was frequently seen at the highest dosage, with numbness and paresthesias appearing in a glove-and-stocking distribution. In some cases, this appeared to be a cumulative effect...
December 1987: Cancer Treatment Reports
https://www.readbyqxmd.com/read/2825994/etoposide-ifosfamide-and-cisplatin-in-the-treatment-of-advanced-non-small-cell-lung-cancer
#2
A Ardizzoni, V Fusco, M Gulisano, P Pronzato, F Baracco, A Capaccio, G Pastorino, M Nosenzo, R Felletti, F Fabiano
No abstract text is available yet for this article.
December 1987: Cancer Treatment Reports
https://www.readbyqxmd.com/read/2446754/phase-ii-study-of-fludarabine-phosphate-in-previously-untreated-patients-with-colorectal-carcinoma-a-southwest-oncology-group-study
#3
W H Harvey, T R Fleming, D D Von Hoff, J G Katterhagen, C A Coltman
No abstract text is available yet for this article.
December 1987: Cancer Treatment Reports
https://www.readbyqxmd.com/read/2446753/phase-ii-trial-of-fludarabine-phosphate-in-patients-with-head-and-neck-cancer-a-southwest-oncology-group-study
#4
G B Weiss, B Metch, D D Von Hoff, S A Taylor, J H Saiers
No abstract text is available yet for this article.
December 1987: Cancer Treatment Reports
https://www.readbyqxmd.com/read/3677112/management-of-learned-food-aversions-in-cancer-patients-receiving-chemotherapy
#5
R D Mattes, C Arnold, M Boraas
Aversions that form towards foods after their ingestion has been associated with illness are termed learned food aversions (LFA). This adverse treatment side effect has been implicated in the anorexia of cancer and can compromise the quality of patients' lives. In an attempt to block the formation or ameliorate the manifestations of this treatment sequela, a nutritionally inconsequential "scapegoat" food was presented to patients just prior to their first course of therapy. The hypothesis was that treatment-related aversions would be targeted towards the scapegoat, thereby sparing acceptable and nutrient-dense items in the patient's typical diet...
November 1987: Cancer Treatment Reports
https://www.readbyqxmd.com/read/2445482/phase-ii-study-of-fludarabine-phosphate-in-previously-untreated-patients-with-hepatoma-a-southwest-oncology-group-study
#6
W H Harvey, T R Fleming, G Beltran, J H Saiers, N Oishi, D D Von Hoff
No abstract text is available yet for this article.
November 1987: Cancer Treatment Reports
https://www.readbyqxmd.com/read/3308078/gallium-nitrate-in-prostatic-cancer-evaluation-of-antitumor-activity-and-effects-on-bone-turnover
#7
H I Scher, T Curley, N Geller, D Dershaw, E Chan, J Nisselbaum, N Alcock, P Hollander, A Yagoda
Gallium nitrate, an agent known to inhibit bone resorption, was evaluated in patients with bidimensionally measurable hormone-refractory prostatic cancer. The starting dose was 200 mg/m2 iv by continuous infusion over 7 days. Two patients (10%; 95% confidence limits, 0%-22%) achieved short partial remissions of 1 and 6+ months, while seven of 23 (30%; 95% confidence limits, 14%-52%) showed a diminution of bone pain. Serial indices of bone turnover including serum calcium, phosphorus, and urinary hydroxyproline excretion showed a significant decrease at the completion of the infusion which returned to baseline prior to the next cycle...
October 1987: Cancer Treatment Reports
https://www.readbyqxmd.com/read/3115570/phase-i-trial-of-combinations-of-recombinant-interferons-beta-ser-and-gamma-in-patients-with-advanced-malignancy
#8
J H Schiller, B Storer, J K Willson, E C Borden
Based upon in vitro and in vivo synergistic activity of Type I and Type II interferons (IFNs) in preclinical in vitro and in vivo studies, we initiated a phase I trial evaluating the doses, safety, and pharmacokinetics of combinations of recombinant DNA-produced human IFN-beta ser and IFN-gamma in 27 patients with cancer. Twenty-four patients were treated with a 2-hour infusion of IFN-gamma, followed by a 10-minute iv injection of IFN-beta ser, three times a week. Patients were entered on fixed dose levels of 1 X 10(6), 3 X 10(6), 10 X 10(6), 30 X 10(6), and 100 X 10(6) units of each IFN...
October 1987: Cancer Treatment Reports
https://www.readbyqxmd.com/read/2820573/unexpected-toxicity-encountered-in-the-national-wilms-tumor-study
#9
LETTER
G J D'Angio
No abstract text is available yet for this article.
October 1987: Cancer Treatment Reports
https://www.readbyqxmd.com/read/3038318/phase-ii-trial-of-oral-piritrexim-bw301u-in-patients-with-stage-iii-non-small-cell-lung-cancer
#10
M G Kris, R J Gralla, M T Burke, L D Berkowitz, L D Marks, D P Kelsen, R T Heelan
No abstract text is available yet for this article.
July 1987: Cancer Treatment Reports
https://www.readbyqxmd.com/read/3552221/indicine-n-oxide-clinical-use-of-a-pyrrolizidine-alkaloid
#11
REVIEW
S A King, M Suffness, B Leyland-Jones, D F Hoth, P J O'Dwyer
No abstract text is available yet for this article.
May 1987: Cancer Treatment Reports
https://www.readbyqxmd.com/read/2436773/evaluation-of-fludarabine-phosphate-in-renal-cell-carcinoma-a-southwest-oncology-group-study
#12
L Balducci, B Blumenstein, D D Von Hoff, M Davis, H E Hynes, R M Bukowski, E D Crawford
No abstract text is available yet for this article.
May 1987: Cancer Treatment Reports
https://www.readbyqxmd.com/read/3815401/phase-ii-studies-of-pcnu-and-bisantrene-in-advanced-renal-cell-carcinoma
#13
P J Elson, R H Earhart, L K Kvols, R Spiegel, A M Keller, M S Kies, T E Davis, C Stevens, L Gumas, D L Trump
No abstract text is available yet for this article.
March 1987: Cancer Treatment Reports
https://www.readbyqxmd.com/read/3815391/weekly-5-fluorouracil-combined-with-pala-toxic-and-therapeutic-effects-in-colorectal-cancer
#14
F M Muggia, F J Camacho, B H Kaplan, M D Green, E S Greenwald, J C Wernz, P F Engstrom
A total of 51 patients (eight previously treated) received PALA added to 5-fluorouracil (5FU) given weekly. After 32 patients, the PALA schedule was changed from every other week to weekly, 24 hours preceding 5FU in accordance with preclinical leads (see text). Both schedules were associated with moderately severe toxic effects related primarily to PALA (skin rash) or to the combined effects of both drugs (diarrhea, vomiting, conjunctivitis, and neurotoxicity). Overall nine partial responses were observed, including three in patients previously treated with 5FU...
March 1987: Cancer Treatment Reports
https://www.readbyqxmd.com/read/3493069/chemoendocrine-therapy-with-prolonged-estrogen-priming-in-advanced-breast-cancer-endocrine-pharmacokinetics-and-toxicity
#15
C Benz, D Gandara, B Miller, T Drakes, S Monroe, B Wilbur, M DeGregorio
Recent efforts to improve response rates in advanced breast cancer have used short, alternating courses of antiestrogen therapy followed by estrogen priming to cytokinetically enhance tumor cell sensitivity to antimetabolites. Based on recent in vitro and in vivo studies, we have introduced a chemoendocrine regimen that uses prolonged courses of estrogen priming. The present protocol consists of alternating monthly cycles of tamoxifen (TAM) and estradiol during which sequential (24-hr) methotrexate, 5-fluorouracil, and leucovorin are administered at 2-week intervals...
March 1987: Cancer Treatment Reports
https://www.readbyqxmd.com/read/3802121/allergy-induced-hepatic-toxicity-associated-with-dacarbazine
#16
E McClay, C J Lusch, M J Mastrangelo
No abstract text is available yet for this article.
February 1987: Cancer Treatment Reports
https://www.readbyqxmd.com/read/3542207/hammering-away-at-solid-tumors
#17
F R Appelbaum
No abstract text is available yet for this article.
February 1987: Cancer Treatment Reports
https://www.readbyqxmd.com/read/3026626/high-dose-carmustine-with-autologous-bone-marrow-transplantation-for-the-adjuvant-treatment-of-high-grade-gliomas-of-the-central-nervous-system
#18
S N Wolff, G L Phillips, G P Herzig
The long-term survival of patients with high-grade gliomas of the CNS is poor despite the use of radiation therapy and chemotherapy. In an attempt to improve the survival of such patients, we administered adjuvant chemotherapy as high-dose carmustine with autologous bone marrow transplantation. Eighteen patients, 15 with glioblastoma multiforme and three with anaplastic astrocytoma, were treated shortly after completion of standard radiation therapy. One course of carmustine was administered at a total dose of 900-1050 mg/m2 iv over 3 days followed in 3 days by the reinfusion of the previously cryopreserved bone marrow...
February 1987: Cancer Treatment Reports
https://www.readbyqxmd.com/read/3791276/phase-ii-trial-of-spirogermanium-in-central-nervous-system-tumors-a-southwest-oncology-group-study
#19
J W Goodwin, J Crowley, B Tranum, R Vance, M Slavik, S Balcerzak, D Hacker
No abstract text is available yet for this article.
January 1987: Cancer Treatment Reports
https://www.readbyqxmd.com/read/3791268/salvage-chemotherapy-of-advanced-lymphoma-with-investigational-drugs-mitoguazone-gallium-nitrate-and-etoposide
#20
R P Warrell, L Danieu, C J Coonley, C Atkins
Patients with advanced lymphoma who relapse from intensive first-line combination chemotherapy generally have a very poor prognosis. The use of investigational drugs which lack cross-resistance to agents commonly used for initial therapy represents an important approach to the management of such patients. Based upon our prior experience, we developed a protocol which employed a combination of three new agents. Mitoguazone (600 mg/m2) was administered on Days 1 and 10; etoposide (100-125 mg/m2) was administered on Days 2, 3, and 4; and gallium nitrate (300 mg/m2/day) was administered as a continuous iv infusion over 24 hours on Days 1-7...
January 1987: Cancer Treatment Reports
journal
journal
26734
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"